Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
Completed · Phase 2
Conditions studied: Lung Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 plus paclitaxel in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
Key facts
- Study ID
- NCT00005849
- Run by
- University of Chicago
- People needed
- 15
- Starts
- 2000-04-01
- Expected to finish
- 2003-11-01
- Last updated by the study team
- 2013-02-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Illinois at Chicago — Chicago, Illinois, United States
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
- Decatur Memorial Hospital Cancer Care Institute — Decatur, Illinois, United States
- Evanston Northwestern Health Care — Evanston, Illinois, United States
- Lutheran General Cancer Care Center — Park Ridge, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
- Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
- Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.